Travere Therapeutics TVTX reported its Q2 earnings results on Thursday, August 4, 2022.
Here's what investors need to know about the announcement.
Earnings
Travere Therapeutics beat estimated earnings by 26.14%, reporting an EPS of $-0.65 versus an estimate of $-0.88.
Revenue was down $450 thousand from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.03 which was followed by a 9.56% drop in the share price the next day.
Here's a look at Travere Therapeutics's past performance:
Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
---|---|---|---|---|
EPS Estimate | -0.85 | -0.72 | -0.54 | -0.68 |
EPS Actual | -0.82 | -0.61 | -0.13 | -0.39 |
Revenue Estimate | 51.92M | 57.81M | 60.93M | 50.33M |
Revenue Actual | 48.49M | 57.25M | 68.22M | 54.62M |
To track all earnings releases for Travere Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.